Diagnostic tools for prostate cancer (PCa) detection have undergone significant advances in recent years aiming for the improvement of diagnostic accuracy, and reduction of overdiagnosis and overtreatment. The introduction of magnetic resonance as the primary imaging approach for PCa nearly two decades ago was also followed by considerable advancements yielding a more selective use of prostate biopsy, reducing the harm associated with the procedure and minimizing overtreatment of non-clinically significant cancers [
1]. However, a persistent challenge in magnetic resonance imaging (MRI) of PCa is the notable number of false-positive cases generated by the method. …